Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks-- and the track records of the firms behind them -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 140,000 members, many of whom demonstrate better investing insight than published analysts do.
After Gilead Sciences
Shares of Gilead Sciences haven't joined the rally the way Pfizer
Gilead's quarterly results beat expectations, and the company raised its guidance for full-year revenue while lowering its forecast for research and development costs. And after success with its other cocktail HIV drugs, investors see that its four-in-one pill, which is in development, could have a big impact in coming years.
Do you think Gilead Sciences deserves its improved status? Add your thoughts in the comments box below, or head over to CAPS to rate the company and check out all the information and opinions the community offers, absolutely free.